CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in the upcoming CDMO Live 2025 conference. Billed as a premiere partnering event for the biopharma outsourcing industry, CDMO Live will take place May 7-8, 2025, in Rotterdam, Netherlands.
During the conference, Jackie Klecker, Lifecore’s executive vice president, quality and development services, will chair a discussion featuring external quality leaders from the CDMO industry. The talk will explore approaches for transforming quality management from a potential bottleneck into a strategic driver of CDMO partnerships. Ms. Klecker is well-positioned to lead the discussion based on her more than 30 years of industry experience in quality, manufacturing, and development, including guiding Lifecore’s quality assurance for over a decade.
Details regarding the discussion are as follows:
To learn more about the CDMO Live 2025 conference, please visit: https://pharmasource.global/events/cdmolive/
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

| Last Trade: | US$7.59 |
| Daily Change: | 0.08 1.07 |
| Daily Volume: | 94,366 |
| Market Cap: | US$284.400M |
November 06, 2025 October 29, 2025 October 28, 2025 August 07, 2025 June 17, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load